Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier ...

FavorablesafetyandtolerabilityprofileofOCU400investigationaldrugproductin RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance

Related Keywords

Los Angeles ,California ,United States ,Tarun Upadhyay ,Lejla Vajzovic ,David Boyer ,Shankar Musunuri ,Head Of Research ,Ocugen Inc ,Retina Vitreous Associates Medical Group ,Linkedin ,Head Of Communications ,Twitter ,Keck School Of Medicine Los Angeles ,Retina Foundation Of The ,Duke University School Of Medicine ,Best Corrected Visual Acuity ,Multi Luminance Mobility Testing ,Low Luminance Visual Acuity ,Retinitis Pigmentosa ,Chief Executive Officer ,Chief Scientific Officer ,Associate Professor ,Duke Vitreoretinal Fellowship Program ,Duke Eye Center ,Duke University School ,David Birch ,Scientific Director ,Retina Foundation ,Clinical Professor ,Keck School ,Medicine Los Angeles ,Retina Vitreous Associates Medical ,Region ,